Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer
George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.